News | Brachytherapy Systems | January 04, 2019

Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer

Patient-reported outcomes show smaller late toxicity profile for brachytherapy with similar progression-free survival to brachytherapy plus external beam therapy

Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer

January 4, 2018 — Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity profile for external beam radiotherapy and brachytherapy (EBT+ B) versus transperineal interstitial permanent brachytherapy (B) alone in men with intermediate-risk prostate cancer. The results from the NRG Oncology trial RTOG 0232, presented at the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, did show similarities in progression-free survival.

NRG-RTOG 0232 evaluated the differences between progression-free survival and patient-reported outcomes on two separate treatment arms. The first arm was treated with combined partial pelvis EBT+B, whereas the second was treated with B alone. Men with prostate carcinoma were randomly assigned to receive treatment on one of the two arms. Researchers measured changes from baseline to 4 and 24 months using expanded prostate index composite (EPIC) and assessed three prostate cancer-specific PRO domains that included bowel, urinary and sexual.

“Although progression-free survival was similar on both treatment arms, the addition of external beam therapy yielded a higher percentage of clinician-reported late grade 3 or greater toxicities. The patient-reported data confirms that brachytherapy alone is the superior treatment for this for men with intermediate risk prostate cancer, with less patient-reported side effects. Brachytherapy alone would also be the most cost efficient treatment option for patients,” stated Deborah W. Bruner, RN, Ph.D., FANN, the abstract’s lead author and the Emory University Senior Vice President for Research.

At 24 months following their treatment, researchers found that the men on the EBT + B arm reported poorer urinary, bowel and sexual PROs and much greater toxicities than the B alone arm. Late grade 3 or greater clinical reported toxicities were 13 percent for the EBT+B arm and 7 percent for the B alone arm. Late grade 3 or greater bladder/genitourinary toxicity, the major symptom of concern, was underreported by clinician-report compared to patient-report. Clinicians reported late grade 3 or greater bladder/genitourinary toxicities of 8 percent for the EBT+B arm and 3 percent for the B alone arm compared to patient reports of 34 percent bladder/genitourinary toxicities for the EBT+B arm and 23 percent for the B alone arm. This further demonstrated the critical role patient-reported outcomes play in assessing treatment efficacy and clinically relevant symptoms.

For more information: www.astro.org

Reference

Bruner D.W., Moughan J., Prestidge B.R., et al. Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer. Abstract presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).

Related Content

Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Study Assesses Risk of MRI Exams for Patients With Tattoos
News | Magnetic Resonance Imaging (MRI) | February 01, 2019
A new European study concluded that magnetic resonance imaging (MRI) exams pose little risk for people with tattoos,...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.